TRPV1 contributes to NGF-induced sensitization but is not required for its development. These findings put TRPV1's potential as a therapeutic target for hyperalgesia into perspective and suggest a potential regulatory role in pain homeostasis.
Blechschmidt et al. (Thu,) studied this question.